[3] A. J. Cann et al., “Reversion to neurovirulence of the live-attenuated sabin type 3 oral

poliovirus vaccine,” Nucleic Acids Res., vol. 12, no. 20, pp. 7787–7792, Oct. 1984.

[4] K. H. Khan, “Gene expression in Mammalian cells and its applications,” Adv.

Pharm. Bull., vol. 3, no. 2, pp. 257–263, 2013.

[5] WHO, “Annex 3 Recommendations for the evaluation of animal cell cultures as

substrates for the manufacture of biological medicinal products and for the char-

acterization of cell banks Replacement of Annex 1 of WHO Technical Report Series,

No. 878,” 2013. https://www.who.int/biologicals/vaccines/TRS_978_Annex_3.pdf

(accessed Oct-2021).

[6] F. Aubrit et al., “Cell substrates for the production of viral vaccines,” Vaccine,

vol. 33, no. 44, pp. 5905–5912, Nov. 2015.

[7] R. I. Freshney, Culture of Animal Cells: A Manual of Basic Technique, 5th Edition.

John Wiley & Sons, Inc.

[8] A. Stokes, “Managing potential virus and TSE contamination | Pharmaceutical en-

gineering March/April,”2018. ( https://ispe.org/pharmaceutical-engineering/march-

april-2018/managing-potential-virus-and-tse-contamination)

[9] P. W. Barone et al., “Viral contamination in biologic manufacture and implications

for emerging therapies,” Nat. Biotechnol. 2020 385, vol. 38, no. 5, pp. 563–572,

Apr. 2020.

[10] D. Onions, C. Côté, B. Love, and J. Kolman, “Deep Sequencing Applications for

Vaccine Development and Safety,” in Vaccine Analysis: Strategies, Principles, and

Control, B. K. Nunnally, V. E. Turula, and R. D. Sitrin, Eds. Berlin, Heidelberg:

Springer-Verlag, 2015, pp. 445–477.

[11] J. Petricciani, R. Sheets, E. Griffiths, and I. Knezevic, “Adventitious agents in viral

vaccines: lessons learned from 4 case studies,” Biologicals, vol. 42, no. 5,

pp. 223–236, Sep. 2014.

[12] J. Victoria et al., “Viral nucleic acids in live-attenuated vaccines: detection of minority

variants and an adventitious virus,” J. Virol., vol. 84, no. 12, pp. 6033–6040, Jun.

2010.

[13] G. Dubin et al., “Investigation of a regulatory agency enquiry into potential porcine

circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and

outcome,” Hum. Vaccine Immunother., vol. 9, no. 11, pp. 2398–2408, Nov. 2013.

[14] R. L. Sheets and P. A. Duncan, “Role of Analytics in Viral Safety,” in Vaccine

Analysis: Strategies, Principles, and Control, B. Nunnally, V. E. Turula, and R.D.

Sitrin, Eds. Berlin, Heidelberg: Springer, 2015.

[15] A. Khan et al., “Advanced Virus Detection Technologies Interest Group

(AVDTIG): Efforts on High Throughput Sequencing (HTS) for virus detection,”

PDA J. Pharm. Sci. Technol., vol. 70, no. 6, pp. 591–595, Nov. 2016.

[16] C. Marcus-Sekura, J. Richardson, R. Harston, N. Sane, and R. Sheets, “Evaluation

of the human host range of bovine and porcine viruses that may contaminate bovine

serum and porcine trypsin used in the manufacture of biological products,”

Biologicals, vol. 39, no. 6, pp. 359–369, Nov. 2011.

[17] L. Gagnieur et al., “Unbiased analysis by high throughput sequencing of the viral

diversity in fetal bovine serum and trypsin used in cell culture,” Biologicals, vol. 42,

no. 3, pp. 145–152, 2014.

[18] ICH, “International conference on harmonisation of technical requirements for re-

gistration of pharmaceuticals for human use ich harmonised tripartite guideline

quality risk management Q9,” 2005. https://database.ich.org/sites/default/files/

Q9%20Guideline.pdf (accessed Oct-2021).

[19] “EDQM (European Directorate for the Quality of Medicines – Council of Europe).

European Pharmacopeia, 9th edition, Strasbourg (France),” 2016.

76

Bioprocessing of Viral Vaccines